BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 567 filers reported holding BIO-TECHNE CORP in Q4 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,936,812 | -16.8% | 43,144 | -0.2% | 0.02% | -13.6% |
| Q2 2023 | $3,530,008 | +10.3% | 43,244 | +0.2% | 0.02% | +4.8% |
| Q1 2023 | $3,200,853 | -9.4% | 43,144 | +1.2% | 0.02% | -16.0% |
| Q4 2022 | $3,534,335 | +17.3% | 42,644 | +301.9% | 0.02% | +13.6% |
| Q3 2022 | $3,014,000 | -18.1% | 10,611 | 0.0% | 0.02% | -12.0% |
| Q2 2022 | $3,678,000 | -14.3% | 10,611 | +7.1% | 0.02% | 0.0% |
| Q1 2022 | $4,292,000 | -16.2% | 9,911 | +0.1% | 0.02% | -7.4% |
| Q4 2021 | $5,122,000 | +7.9% | 9,900 | +1.0% | 0.03% | 0.0% |
| Q3 2021 | $4,749,000 | +7.4% | 9,800 | -0.2% | 0.03% | +3.8% |
| Q2 2021 | $4,421,000 | -19.7% | 9,819 | -31.9% | 0.03% | -25.7% |
| Q1 2021 | $5,507,000 | +23.7% | 14,419 | +2.9% | 0.04% | +16.7% |
| Q4 2020 | $4,452,000 | +28.2% | 14,019 | 0.0% | 0.03% | +7.1% |
| Q3 2020 | $3,473,000 | -5.5% | 14,019 | +0.7% | 0.03% | -12.5% |
| Q2 2020 | $3,676,000 | +82.9% | 13,919 | +31.3% | 0.03% | +45.5% |
| Q1 2020 | $2,010,000 | -18.3% | 10,600 | -5.4% | 0.02% | +10.0% |
| Q4 2019 | $2,459,000 | +14.3% | 11,200 | +1.8% | 0.02% | +5.3% |
| Q3 2019 | $2,152,000 | -7.8% | 11,000 | -1.8% | 0.02% | -9.5% |
| Q2 2019 | $2,335,000 | -12.9% | 11,200 | -17.0% | 0.02% | -4.5% |
| Q1 2019 | $2,680,000 | +37.2% | 13,500 | 0.0% | 0.02% | +22.2% |
| Q4 2018 | $1,954,000 | -31.6% | 13,500 | -3.6% | 0.02% | -14.3% |
| Q3 2018 | $2,858,000 | +40.0% | 14,000 | +1.4% | 0.02% | +31.2% |
| Q2 2018 | $2,042,000 | -1.3% | 13,800 | +0.7% | 0.02% | -5.9% |
| Q1 2018 | $2,069,000 | +18.3% | 13,700 | +1.5% | 0.02% | +21.4% |
| Q4 2017 | $1,749,000 | +3.4% | 13,500 | -3.6% | 0.01% | 0.0% |
| Q3 2017 | $1,692,000 | -6.5% | 14,000 | -9.1% | 0.01% | 0.0% |
| Q2 2017 | $1,810,000 | +17.2% | 15,400 | +1.3% | 0.01% | +16.7% |
| Q1 2017 | $1,545,000 | +0.2% | 15,200 | +1.3% | 0.01% | 0.0% |
| Q4 2016 | $1,542,000 | -6.1% | 15,000 | 0.0% | 0.01% | -7.7% |
| Q3 2016 | $1,643,000 | -2.2% | 15,000 | +0.7% | 0.01% | 0.0% |
| Q2 2016 | $1,680,000 | +20.1% | 14,900 | +0.7% | 0.01% | +18.2% |
| Q1 2016 | $1,399,000 | +5.7% | 14,800 | +0.7% | 0.01% | +10.0% |
| Q4 2015 | $1,323,000 | -15.4% | 14,700 | -13.0% | 0.01% | -16.7% |
| Q3 2015 | $1,563,000 | -6.1% | 16,900 | 0.0% | 0.01% | 0.0% |
| Q2 2015 | $1,664,000 | -1.2% | 16,900 | +0.6% | 0.01% | 0.0% |
| Q1 2015 | $1,685,000 | +3.6% | 16,800 | -4.5% | 0.01% | +9.1% |
| Q4 2014 | $1,626,000 | – | 17,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |